28.09.2012 - German university hospital Charité and French pharma company Sanofi have agreed to expand their joint research efforts to the field of diabetes.
The partnership of the Charité and Sanofi had begun in summer 2010, initially with a focus in the field of stroke research. Following a decision on 27 September, scientists and clinicians from both sides will now work together in the field of diabetes research as well. The goal is to better understand the medical needs of patients and to find new targeted approaches to cure or treat the disease.
The partners have already agreed on a first target molecule to investigate further. Researchers from Charité discovered the yet undisclosed molecule, which will now fuel a core project at the newly founded Sanofi-Charité-diabetic laboratory. The target molecule seems to be promising, as results from laboratory tests indicate that it inhibition might protect the body from diet-and age-induced obesity and insulin resistance. “With Charité we have built a highly efficient scientific cooperation over the past two years,” said Jochen Maas, Director of Research and Development of Sanofi-Aventis Deutschland GmbH and head of the German research and development center of Sanofi.
Karl Max Einhäupl, CEO of the Charité, welcomed the enhanced cooperation as well: “Diabetes is a major challenge for our health system. Bringing together the clinical experience and the academic performance of physicians and scientists of the Charité with the development and application expertise of Sanofi, will generate valuable inputs for the development of successful diabetes therapies.”
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.